Investment Thesis
Rein Therapeutics is a pre-revenue pharmaceutical company facing an acute financial crisis with only ~12-18 months of cash runway ($4.4M cash against $3.6M annual cash burn) and severely impaired liquidity (0.40x current ratio). The company burns $3.4M in operating cash flow annually with zero revenue, and current liabilities exceed current assets by 2.5x, indicating imminent insolvency without capital infusion.
Strengths
- Minimal debt burden with no long-term debt obligation
- Positive stockholders equity of $11.6M provides some asset cushion
- Limited insider selling activity suggests limited insider concern about immediate collapse
Risks
- Zero revenue with no commercialized products or clear path to revenue
- Critical cash runway of 12-18 months at current burn rate before insolvency
- Severe liquidity crisis: 0.40x current ratio means liabilities exceed liquid assets by 2.5x, unable to meet short-term obligations
- Negative operating cash flow of -$3.4M annually indicates core R&D operations are not self-sustaining
- Highly dilutive capital raise likely required within 12 months, destroying shareholder value
Key Metrics to Watch
- Monthly cash burn rate and remaining runway (urgency of capital needs)
- Product development milestones and clinical trial progress toward revenue
- Equity raise activity and dilution impact on existing shareholders
Financial Metrics
Revenue
0.0
Net Income
-5.8M
EPS (Diluted)
$-0.19
Free Cash Flow
-3.6M
Total Assets
26.3M
Cash
4.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-50.4%
ROA
-22.2%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.40x
Quick Ratio
0.40x
Debt/Equity
0.00x
Debt/Assets
55.9%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T09:11:56.069894 |
Data as of: 2026-03-31 |
Powered by Claude AI